Literature DB >> 16331611

Prognostic significance of osteopontin expression in human prostate cancer.

Shiva S Forootan1, Christopher S Foster, Vijay R Aachi, Janet Adamson, Paul H Smith, Ke Lin, Youqiang Ke.   

Abstract

To test the hypothesis that expression of osteopontin (OPN), an integrin-binding glycoprotein, can independently predict the potential aggressiveness of prostate cancer, the status of OPN expression in benign and malignant prostate cancer cell lines and tissues was analysed by Western blot and immunohistochemistry. Amongst the four prostate cell lines analysed, the level of OPN expressed in the benign PNT-2 cells was set at 1, the relative level of OPN expressed in the weakly malignant cell line LNCaP was increased to 1.5. In the highly malignant cell lines Du-145 and PC-3, the level of OPN expression was further increased to 2.9 and 4.4, respectively. An increased expression of OPN was also observed in the prostate tissue samples. When the level of OPN in normal tissue was set at 1, its level in benign prostate hyperplasia (BPH) was similar at 0.99 +/- 0.2, whereas the OPN level in the highly malignant carcinoma tissue was greatly increased by nearly 6-fold to 5.9 +/- 0.3. Amongst the 116 cases examined immunocytochemically, of the 10 normal cases, 3 (30%) were unstained and 7 (70%) stained weakly positive (+). Amongst the 36 BPH samples, 32 (89%) stained weakly positive (+) and 4 (11%) were unstained (-). For the 70 carcinomas analysed, 31 (44%) stained strongly positive (+++), 20 (29%) stained moderately positive (++) and 19 (27%) stained weakly positive (+). These results showed that the level of OPN expressed between the normal and the BPH samples was not significantly different (Fisher's exact test, p = 0.16). However, in comparison to that in the BPH samples, the expression of OPN in the carcinoma tissues was significantly increased (Chi-square test, p < 0.0001). Kaplan-Meier survival analysis showed that the increased level of OPN expression was significantly (n = 70, p = 0.03) associated with reduced survival time of the patients. The OPN expression was increased with the increasing Gleason scores of the carcinomas (Chi-square test, p < 0.001). The results in our study support our hypothesis and suggest that the increased OPN level may be involved in the malignant transformation of prostate epithelial cells and OPN expression level is an important determinant for patient survival. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331611     DOI: 10.1002/ijc.21619

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells.

Authors:  Carolina Castilla; M Luz Flores; José M Conde; Rafael Medina; Francisco J Torrubia; Miguel A Japón; Carmen Sáez
Journal:  Clin Exp Metastasis       Date:  2012-01-25       Impact factor: 5.150

3.  Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.

Authors:  Petra Popovics; Wisam N Awadallah; Sarah E Kohrt; Thomas C Case; Nicole L Miller; Emily A Ricke; Wei Huang; Marisol Ramirez-Solano; Qi Liu; Chad M Vezina; Robert J Matusik; William A Ricke; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-05-01       Impact factor: 4.104

4.  Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.

Authors:  Daniel J Caruso; Adrienne J K Carmack; Vinata B Lokeshwar; Robert C Duncan; Mark S Soloway; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

5.  Osteopontin is a tumor autoantigen in prostate cancer patients.

Authors:  Tatiana M Tilli; Eloísio A Silva; Lívia C Matos; Douglas V Faget; Bianca F P Dias; Juliana S P Vasconcelos; Yasuyuki Yokosaki; Etel R P Gimba
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

6.  Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Authors:  Xianmin Luo; Megan K Ruhland; Ermira Pazolli; Anne C Lind; Sheila A Stewart
Journal:  Mol Cancer Res       Date:  2011-06-14       Impact factor: 5.852

7.  The immunohistochemical expression profile of osteopontin in normal human tissues using two site-specific antibodies reveals a wide distribution of positive cells and extensive expression in the central and peripheral nervous systems.

Authors:  Yasuto Kunii; Shin-ichi Niwa; Yoshiaki Hagiwara; Masahiro Maeda; Tsutomu Seitoh; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2009-09-26       Impact factor: 2.309

8.  Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.

Authors:  Matthias Bache; Matthias Kappler; Henri Wichmann; Swetlana Rot; Antje Hahnel; Thomas Greither; Harun M Said; Matthias Kotzsch; Peter Würl; Helge Taubert; Dirk Vordermark
Journal:  BMC Cancer       Date:  2010-04-08       Impact factor: 4.430

Review 9.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

10.  Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis.

Authors:  Lara H El Touny; Partha P Banerjee
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.